Gilead Sciences: A Good Set Up for Earnings Beats?
Barclays analyst Geoff Meacham and team argue that sales of Gilead Sciences’ (GILD) hepatitis-C drugs could surprise to the upside: In 2016, Street forecasts for Gilead’s hepatitis C (hep C) franchise call for a ~20% y/y decline in US sales. Continue reading